Re: RCPT meets MS primary endpoint in phase-2 portion of trial
Will be interesting to see clinical trials data from other next generation S1P modulators, as there are differences between them regarding S1PR selectivity and potency and it remains to be determined which one has the best profile.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.